Clinical Trial Update: Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating pevonedistat with carboplatin and paclitaxel in advanced non-small cell lung cancer patients previously treated with im…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-15